22157.jpg
Worldwide Nanobiotechnology Industry to 2029 - Featuring Aduro BioTech, Calando Pharmaceuticals and Baxter International Among Others
April 29, 2021 07:28 ET | Research and Markets
Dublin, April 29, 2021 (GLOBE NEWSWIRE) -- The "Nanobiotechnology Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts,...
Unknown.png
Arch Therapeutics to Provide Corporate Update at the 2019 BIO CEO & Investor Conference
February 05, 2019 07:50 ET | Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
Unknown.png
Arch Therapeutics to Provide Corporate Update at the 11th Annual Biotech Showcase™ 2019 Conference on January 8th, 2019
December 20, 2018 07:50 ET | Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
Unknown.png
Arch Therapeutics Receives 510(k) Clearance from the US FDA for AC5™ Topical Gel
December 17, 2018 07:50 ET | Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Unknown.png
Arch Therapeutics Provided Corporate Update at the 11th Annual LD Micro Main Event
December 06, 2018 07:50 ET | Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Unknown.png
Arch Therapeutics Announces Positive Outcome of Ruling from Japanese Intellectual Property High Court
December 04, 2018 07:50 ET | Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, is...